Donald E Jr Bobo

CVP Donald E Jr Bobo sells 23,145 EW shares at $86.42; stock near 52-week high; 0 of 5 prior same-ticker sells well-timed.

Donald E Jr Bobo, CVP of Strategy and Corporate Development, sold 23,145 shares at $86.42, reducing holdings by 19.0% to 98,611 shares. The sale occurred near the 52-week high ($87.93), with the current price at $86.51 just 1.6% below peak. Edwards Lifesciences shows solid fundamentals (11.6% annual revenue growth, $380.7M net income on $1.6B quarterly revenue, P/E of 45.53), supporting valuations around these levels. Notably, across his five prior same-ticker trades, 0 of 5 sells showed negative 90-day returns (well-timed indicator for sell activity), suggesting a pattern of selling into strength rather than ahead of declines. While his cross-ticker track record shows a 37.50% well-timed rate on 8 sells, this ticker-specific history of selling at or near peaks without subsequent downside protection offers a less favorable signal for position conviction.

CVP Donald E Jr Bobo sold 17,968 shares at EW for $1,472,678.46 on 2026-05-15; reduces holdings 36.7%.

Donald E Jr Bobo, CVP of Strategy and Corporate Development, executed 2 separate sales totaling 17,968 shares for $1,472,678.46 at a blended average price of $81.96 on 2026-05-15. The transaction represents a -36.7% reduction in his holdings, from 48,937 shares to 30,969 shares post-sale. At the time of the filing, the stock traded at $82.39, within its 52-week range of $72.30–$87.89 and -6.3% from the 52-week high. Edwards Lifesciences reported latest-quarter revenue of $1,648,600,000.00 and net income of $380,700,000.00, with annual revenue growth of +11.6% and a P/E of 43.36. The magnitude and composition of this sale—two distinct transactions executed the same day—warrant attention to the timing and context of his decision relative to the company's fundamentals and his own transaction history.

CVP Donald E Bobo Jr sold 22.7K EW shares for $1.8M at $80.16 avg, cutting holdings by 51.6%

Donald E Bobo Jr, CVP of Strategy and Corporate Development, executed two separate sales on 2026-04-02 totaling 22,680 shares for $1,818,055.25, reducing his stake from 43,946 to 21,266 shares—a 51.6% reduction in holdings. His cross-ticker track record shows a 90-day well-timed rate of 100.00% across 4 prior sells, with an average 90-day return of -1.6% after those sales; at Edwards Lifesciences specifically, 3 of his 3 prior measurable sales (2024-03-13, 2024-04-08, 2024-04-08) were well-timed at the 90-day mark, with returns of -4.4%, -0.4%, and -0.0% respectively. The current sale occurred at $80.16 while the stock now trades at $81.05 (within the 52-week range of $67.07–$87.18 and -7.0% from its high), with recent momentum at -5.0% over both 30 and 90 days. This substantial reduction in position size by a senior executive responsible for strategy deserves monitoring for any signals regarding management's internal view of value or forward prospects.

CVP Donald E Bobo Jr sold 24,000 EW shares at $83.84 on 2026-02-25; 90d timing pattern suggests well-timed exit consistent with his prior 3 trades at this ticker.

Donald E Bobo Jr, CVP of Strategy/Corporate Development, executed a substantial sale of 24,000 shares ($2.0M) at $83.84, reducing his holdings from 45.3K to 21.3K shares (-53.0%). His prior 3 trades at Edwards Lifesciences all displayed negative 90-day returns (-8.2%, -0.4%, and -0.4%), meaning he consistently sold before subsequent declines. His cross-ticker track record shows a 90-day well-timed rate of 100.00% across 3 prior sells with an average 90d return of -1.6%. The current price of $85.90 represents a 1.2% pullback from the 52-week high of $86.94, placing the company in a stretched valuation context (P/E of 46.68) despite solid fundamentals (revenue growth of +11.6%, $291.1M net income). The confluence of a pattern of well-timed exits at this specific ticker and systematic positive timing across his full trading history suggests a deliberate reduction ahead of potential near-term weakness.